Releases › ICD-10-CM FY2025
ICD-10-CM FY2025
Effective 2024-10-01 to 2025-03-31. 74,260 codes in the release.
291added
15revised
3removed
Codes added 291
| Code | Description |
|---|---|
| C81.0A | Nodular lymphocyte predominant Hodgkin lymphoma, in remission |
| C81.1A | Nodular sclerosis Hodgkin lymphoma, in remission |
| C81.2A | Mixed cellularity Hodgkin lymphoma, in remission |
| C81.3A | Lymphocyte depleted Hodgkin lymphoma, in remission |
| C81.4A | Lymphocyte-rich Hodgkin lymphoma, in remission |
| C81.7A | Other Hodgkin lymphoma, in remission |
| C81.9A | Hodgkin lymphoma, unspecified, in remission |
| C82.0A | Follicular lymphoma grade I, in remission |
| C82.1A | Follicular lymphoma grade II, in remission |
| C82.2A | Follicular lymphoma grade III, unspecified, in remission |
| C82.3A | Follicular lymphoma grade IIIa, in remission |
| C82.4A | Follicular lymphoma grade IIIb, in remission |
| C82.5A | Diffuse follicle center lymphoma, in remission |
| C82.6A | Cutaneous follicle center lymphoma, in remission |
| C82.8A | Other types of follicular lymphoma, in remission |
| C82.9A | Follicular lymphoma, unspecified, in remission |
| C83.0A | Small cell B-cell lymphoma, in remission |
| C83.1A | Mantle cell lymphoma, in remission |
| C83.390 | Primary central nervous system lymphoma |
| C83.398 | Diffuse large B-cell lymphoma of other extranodal and solid organ sites |
| C83.3A | Diffuse large B-cell lymphoma, in remission |
| C83.5A | Lymphoblastic (diffuse) lymphoma, in remission |
| C83.7A | Burkitt lymphoma, in remission |
| C83.8A | Other non-follicular lymphoma, in remission |
| C83.9A | Non-follicular (diffuse) lymphoma, unspecified, in remission |
| C84.0A | Mycosis fungoides, in remission |
| C84.1A | Sezary disease, in remission |
| C84.4A | Peripheral T-cell lymphoma, not elsewhere classified, in remission |
| C84.6A | Anaplastic large cell lymphoma, ALK-positive, in remission |
| C84.7B | Anaplastic large cell lymphoma, ALK-negative, in remission |
| C84.9A | Mature T/NK-cell lymphomas, unspecified, in remission |
| C84.AA | Cutaneous T-cell lymphoma, unspecified, in remission |
| C84.ZA | Other mature T/NK-cell lymphomas, in remission |
| C85.1A | Unspecified B-cell lymphoma, in remission |
| C85.2A | Mediastinal (thymic) large B-cell lymphoma, in remission |
| C85.8A | Other specified types of non-Hodgkin lymphoma, in remission |
| C85.9A | Non-Hodgkin lymphoma, unspecified, in remission |
| C86.00 | Extranodal NK/T-cell lymphoma, nasal type not having achieved remission |
| C86.01 | Extranodal NK/T-cell lymphoma, nasal type, in remission |
| C86.10 | Hepatosplenic T-cell lymphoma not having achieved remission |
| C86.11 | Hepatosplenic T-cell lymphoma, in remission |
| C86.20 | Enteropathy-type (intestinal) T-cell lymphoma not having achieved remission |
| C86.21 | Enteropathy-type (intestinal) T-cell lymphoma, in remission |
| C86.30 | Subcutaneous panniculitis-like T-cell lymphoma not having achieved remission |
| C86.31 | Subcutaneous panniculitis-like T-cell lymphoma, in remission |
| C86.40 | Blastic NK-cell lymphoma not having achieved remission |
| C86.41 | Blastic NK-cell lymphoma, in remission |
| C86.50 | Angioimmunoblastic T-cell lymphoma not having achieved remission |
| C86.51 | Angioimmunoblastic T-cell lymphoma, in remission |
| C86.60 | Primary cutaneous CD30-positive T-cell proliferations not having achieved remission |
| C86.61 | Primary cutaneous CD30-positive T-cell proliferations, in remission |
| C88.00 | Waldenstrom macroglobulinemia not having achieved remission |
| C88.01 | Waldenstrom macroglobulinemia, in remission |
| C88.20 | Heavy chain disease not having achieved remission |
| C88.21 | Heavy chain disease, in remission |
| C88.30 | Immunoproliferative small intestinal disease not having achieved remission |
| C88.31 | Immunoproliferative small intestinal disease, in remission |
| C88.40 | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] not having achieved remission |
| C88.41 | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma], in remission |
| C88.80 | Other malignant immunoproliferative diseases not having achieved remission |
| C88.81 | Other malignant immunoproliferative diseases, in remission |
| C88.90 | Malignant immunoproliferative disease, unspecified not having achieved remission |
| C88.91 | Malignant immunoproliferative disease, unspecified, in remission |
| D61.03 | Fanconi anemia |
| E10.A | Type 1 diabetes mellitus, presymptomatic |
| E10.A0 | Type 1 diabetes mellitus, presymptomatic, unspecified |
| E10.A1 | Type 1 diabetes mellitus, presymptomatic, Stage 1 |
| E10.A2 | Type 1 diabetes mellitus, presymptomatic, Stage 2 |
| E16.A | Hypoglycemia level |
| E16.A1 | Hypoglycemia level 1 |
| E16.A2 | Hypoglycemia level 2 |
| E16.A3 | Hypoglycemia level 3 |
| E34.00 | Carcinoid syndrome, unspecified |
| E34.01 | Carcinoid heart syndrome |
| E34.09 | Other carcinoid syndrome |
| E66.81 | Obesity class |
| E66.811 | Obesity, class 1 |
| E66.812 | Obesity, class 2 |
| E66.813 | Obesity, class 3 |
| E66.89 | Other obesity not elsewhere classified |
| E74.82 | Disorders of citrate metabolism |
| E74.820 | SLC13A5 Citrate Transporter Disorder |
| E74.829 | Other disorders of citrate metabolism |
| E88.82 | Obesity due to disruption of MC4R pathway |
| F50.010 | Anorexia nervosa, restricting type, mild |
| F50.011 | Anorexia nervosa, restricting type, moderate |
| F50.012 | Anorexia nervosa, restricting type, severe |
| F50.013 | Anorexia nervosa, restricting type, extreme |
| F50.014 | Anorexia nervosa, restricting type, in remission |
| F50.019 | Anorexia nervosa, restricting type, unspecified |
| F50.020 | Anorexia nervosa, binge eating/purging type, mild |
| F50.021 | Anorexia nervosa, binge eating/purging type, moderate |
| F50.022 | Anorexia nervosa, binge eating/purging type, severe |
| F50.023 | Anorexia nervosa, binge eating/purging type, extreme |
| F50.024 | Anorexia nervosa, binge eating/purging type, in remission |
| F50.029 | Anorexia nervosa, binge eating/purging type, unspecified |
| F50.20 | Bulimia nervosa, unspecified |
| F50.21 | Bulimia nervosa, mild |
| F50.22 | Bulimia nervosa, moderate |
| F50.23 | Bulimia nervosa, severe |
| F50.24 | Bulimia nervosa, extreme |
| F50.25 | Bulimia nervosa, in remission |
| F50.810 | Binge eating disorder, mild |
| F50.811 | Binge eating disorder, moderate |
| F50.812 | Binge eating disorder, severe |
| F50.813 | Binge eating disorder, extreme |
| F50.814 | Binge eating disorder, in remission |
| F50.819 | Binge eating disorder, unspecified |
| F50.83 | Pica in adults |
| F50.84 | Rumination disorder in adults |
| G40.84 | KCNQ2-related epilepsy |
| G40.841 | KCNQ2-related epilepsy, not intractable, with status epilepticus |
| G40.842 | KCNQ2-related epilepsy, not intractable, without status epilepticus |
| G40.843 | KCNQ2-related epilepsy, intractable, with status epilepticus |
| G40.844 | KCNQ2-related epilepsy, intractable, without status epilepticus |
| G90.81 | Serotonin syndrome |
| G90.89 | Other disorders of autonomic nervous system |
| G93.45 | Developmental and epileptic encephalopathy |
| I26.03 | Cement embolism of pulmonary artery with acute cor pulmonale |
| I26.04 | Fat embolism of pulmonary artery with acute cor pulmonale |
| I26.95 | Cement embolism of pulmonary artery without acute cor pulmonale |
| I26.96 | Fat embolism of pulmonary artery without acute cor pulmonale |
| J34.82 | Nasal valve collapse |
| J34.820 | Internal nasal valve collapse |
| J34.8200 | Internal nasal valve collapse, unspecified |
| J34.8201 | Internal nasal valve collapse, static |
| J34.8202 | Internal nasal valve collapse, dynamic |
| J34.821 | External nasal valve collapse |
| J34.8210 | External nasal valve collapse, unspecified |
| J34.8211 | External nasal valve collapse, static |
| J34.8212 | External nasal valve collapse, dynamic |
| J34.829 | Nasal valve collapse, unspecified |
| K60.30 | Anal fistula, unspecified |
| K60.31 | Anal fistula, simple |
| K60.311 | Anal fistula, simple, initial |
| K60.312 | Anal fistula, simple, persistent |
| K60.313 | Anal fistula, simple, recurrent |
| K60.319 | Anal fistula, simple, unspecified |
| K60.32 | Anal fistula, complex |
| K60.321 | Anal fistula, complex, initial |
| K60.322 | Anal fistula, complex, persistent |
| K60.323 | Anal fistula, complex, recurrent |
| K60.329 | Anal fistula, complex, unspecified |
| K60.40 | Rectal fistula, unspecified |
| K60.41 | Rectal fistula, simple |
| K60.411 | Rectal fistula, simple, initial |
| K60.412 | Rectal fistula, simple, persistent |
| K60.413 | Rectal fistula, simple, recurrent |
| K60.419 | Rectal fistula, simple, unspecified |
| K60.42 | Rectal fistula, complex |
| K60.421 | Rectal fistula, complex, initial |
| K60.422 | Rectal fistula, complex, persistent |
| K60.423 | Rectal fistula, complex, recurrent |
| K60.429 | Rectal fistula, complex, unspecified |
| K60.50 | Anorectal fistula, unspecified |
| K60.51 | Anorectal fistula, simple |
| K60.511 | Anorectal fistula, simple, initial |
| K60.512 | Anorectal fistula, simple, persistent |
| K60.513 | Anorectal fistula, simple, recurrent |
| K60.519 | Anorectal fistula, simple, unspecified |
| K60.52 | Anorectal fistula, complex |
| K60.521 | Anorectal fistula, complex, initial |
| K60.522 | Anorectal fistula, complex, persistent |
| K60.523 | Anorectal fistula, complex, recurrent |
| K60.529 | Anorectal fistula, complex, unspecified |
| L29.81 | Cholestatic pruritus |
| L29.89 | Other pruritus |
| L66.10 | Lichen planopilaris, unspecified |
| L66.11 | Classic lichen planopilaris |
| L66.12 | Frontal fibrosing alopecia |
| L66.19 | Other lichen planopilaris |
| L66.81 | Central centrifugal cicatricial alopecia |
| L66.89 | Other cicatricial alopecia |
| M51.360 | Other intervertebral disc degeneration, lumbar region with discogenic back pain only |
| M51.361 | Other intervertebral disc degeneration, lumbar region with lower extremity pain only |
| M51.362 | Other intervertebral disc degeneration, lumbar region with discogenic back pain and lower extremity pain |
| M51.369 | Other intervertebral disc degeneration, lumbar region without mention of lumbar back pain or lower extremity pain |
| M51.370 | Other intervertebral disc degeneration, lumbosacral region with discogenic back pain only |
| M51.371 | Other intervertebral disc degeneration, lumbosacral region with lower extremity pain only |
| M51.372 | Other intervertebral disc degeneration, lumbosacral region with discogenic back pain and lower extremity pain |
| M51.379 | Other intervertebral disc degeneration, lumbosacral region without mention of lumbar back pain or lower extremity pain |
| M62.85 | Dysfunction of the multifidus muscles, lumbar region |
| M65.90 | Unspecified synovitis and tenosynovitis, unspecified site |
| M65.91 | Unspecified synovitis and tenosynovitis, shoulder |
| M65.911 | Unspecified synovitis and tenosynovitis, right shoulder |
| M65.912 | Unspecified synovitis and tenosynovitis, left shoulder |
| M65.919 | Unspecified synovitis and tenosynovitis, unspecified shoulder |
| M65.92 | Unspecified synovitis and tenosynovitis, upper arm |
| M65.921 | Unspecified synovitis and tenosynovitis, right upper arm |
| M65.922 | Unspecified synovitis and tenosynovitis, left upper arm |
| M65.929 | Unspecified synovitis and tenosynovitis, unspecified upper arm |
| M65.93 | Unspecified synovitis and tenosynovitis, forearm |
| M65.931 | Unspecified synovitis and tenosynovitis, right forearm |
| M65.932 | Unspecified synovitis and tenosynovitis, left forearm |
| M65.939 | Unspecified synovitis and tenosynovitis, unspecified forearm |
| M65.94 | Unspecified synovitis and tenosynovitis, hand |
| M65.941 | Unspecified synovitis and tenosynovitis, right hand |
| M65.942 | Unspecified synovitis and tenosynovitis, left hand |
| M65.949 | Unspecified synovitis and tenosynovitis, unspecified hand |
| M65.95 | Unspecified synovitis and tenosynovitis, thigh |
| M65.951 | Unspecified synovitis and tenosynovitis, right thigh |
| M65.952 | Unspecified synovitis and tenosynovitis, left thigh |
| M65.959 | Unspecified synovitis and tenosynovitis, unspecified thigh |
| M65.96 | Unspecified synovitis and tenosynovitis, lower leg |
| M65.961 | Unspecified synovitis and tenosynovitis, right lower leg |
| M65.962 | Unspecified synovitis and tenosynovitis, left lower leg |
| M65.969 | Unspecified synovitis and tenosynovitis, unspecified lower leg |
| M65.97 | Unspecified synovitis and tenosynovitis, ankle and foot |
| M65.971 | Unspecified synovitis and tenosynovitis, right ankle and foot |
| M65.972 | Unspecified synovitis and tenosynovitis, left ankle and foot |
| M65.979 | Unspecified synovitis and tenosynovitis, unspecified ankle and foot |
| M65.98 | Unspecified synovitis and tenosynovitis, other site |
| M65.99 | Unspecified synovitis and tenosynovitis, multiple sites |
| Q23.81 | Bicuspid aortic valve |
| Q23.82 | Congenital mitral valve cleft leaflet |
| Q23.88 | Other congenital malformations of aortic and mitral valves |
| Q87.86 | Kleefstra syndrome |
| R41.85 | Anosognosia |
| T45.A | Poisoning by, adverse effect of and underdosing of immune checkpoint inhibitors and immunostimulant drugs |
| T45.AX | Poisoning by, adverse effect of and underdosing of immune checkpoint inhibitors and immunostimulant drugs |
| T45.AX1 | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional) |
| T45.AX1A | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), initial encounter |
| T45.AX1D | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), subsequent encounter |
| T45.AX1S | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), sequela |
| T45.AX2 | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm |
| T45.AX2A | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, initial encounter |
| T45.AX2D | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, subsequent encounter |
| T45.AX2S | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, sequela |
| T45.AX3 | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault |
| T45.AX3A | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, initial encounter |
| T45.AX3D | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, subsequent encounter |
| T45.AX3S | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, sequela |
| T45.AX4 | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined |
| T45.AX4A | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, initial encounter |
| T45.AX4D | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, subsequent encounter |
| T45.AX4S | Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, sequela |
| T45.AX5 | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs |
| T45.AX5A | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter |
| T45.AX5D | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter |
| T45.AX5S | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela |
| T45.AX6 | Underdosing of immune checkpoint inhibitors and immunostimulant drugs |
| T45.AX6A | Underdosing of immune checkpoint inhibitors and immunostimulant drugs, initial encounter |
| T45.AX6D | Underdosing of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter |
| T45.AX6S | Underdosing of immune checkpoint inhibitors and immunostimulant drugs, sequela |
| T81.320 | Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure |
| T81.320A | Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, initial encounter |
| T81.320D | Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, subsequent encounter |
| T81.320S | Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, sequela |
| T81.321 | Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia |
| T81.321A | Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, initial encounter |
| T81.321D | Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, subsequent encounter |
| T81.321S | Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, sequela |
| T81.328 | Disruption or dehiscence of closure of other specified internal operation (surgical) wound |
| T81.328A | Disruption or dehiscence of closure of other specified internal operation (surgical) wound, initial encounter |
| T81.328D | Disruption or dehiscence of closure of other specified internal operation (surgical) wound, subsequent encounter |
| T81.328S | Disruption or dehiscence of closure of other specified internal operation (surgical) wound, sequela |
| T81.329 | Deep disruption or dehiscence of operation wound, unspecified |
| T81.329A | Deep disruption or dehiscence of operation wound, unspecified, initial encounter |
| T81.329D | Deep disruption or dehiscence of operation wound, unspecified, subsequent encounter |
| T81.329S | Deep disruption or dehiscence of operation wound, unspecified, sequela |
| Z15.1 | Genetic susceptibility to epilepsy and neurodevelopmental disorders |
| Z15.2 | Genetic susceptibility to obesity |
| Z17.2 | Progesterone receptor status |
| Z17.21 | Progesterone receptor positive status |
| Z17.22 | Progesterone receptor negative status |
| Z17.3 | Human epidermal growth factor 2 receptor |
| Z17.31 | Human epidermal growth factor receptor 2 positive status |
| Z17.32 | Human epidermal growth factor receptor 2 negative status |
| Z17.4 | Combined receptor status |
| Z17.41 | Hormone receptor positive |
| Z17.410 | Hormone receptor positive with human epidermal growth factor receptor 2 positive status |
| Z17.411 | Hormone receptor positive with human epidermal growth factor receptor 2 negative status |
| Z17.42 | Hormone receptor negative |
| Z17.420 | Hormone receptor negative with human epidermal growth factor receptor 2 positive status |
| Z17.421 | Hormone receptor negative with human epidermal growth factor receptor 2 negative status |
| Z51.A | Encounter for sepsis aftercare |
| Z59.71 | Insufficient health insurance coverage |
| Z59.72 | Insufficient welfare support |
| Z67.A | Duffy phenotype |
| Z67.A1 | Duffy null |
| Z67.A2 | Duffy a positive |
| Z67.A3 | Duffy b positive |
| Z67.A4 | Duffy a and b positive |
| Z68.55 | Body mass index [BMI] pediatric, 120% of the 95th percentile for age to less than 140% of the 95th percentile for age |
| Z68.56 | Body mass index [BMI] pediatric, greater than or equal to 140% of the 95th percentile for age |
| Z83.72 | Family history of familial adenomatous polyposis |
| Z86.0100 | Personal history of colon polyps, unspecified |
| Z86.0101 | Personal history of adenomatous and serrated colon polyps |
| Z86.0102 | Personal history of hyperplastic colon polyps |
| Z86.0109 | Personal history of other colon polyps |
| Z92.26 | Personal history of immune checkpoint inhibitor therapy |
Descriptions revised 15
| Code | Was, and is now |
|---|---|
| A77.41 | |
| F98.21 | |
| G93.42 | |
| H44.2A3 | |
| H44.2B3 | |
| H44.2C3 | |
| H44.2D3 | |
| H44.2E3 | |
| I26.93 | |
| I26.94 | |
| K58.9 | |
| Q13.81 | |
| Z17 | |
| Z68.54 | |
| Z86.010 |
Codes removed 3
| Code | Description |
|---|---|
| T81.32XA | Disruption of internal operation (surgical) wound, not elsewhere classified, initial encounter |
| T81.32XD | Disruption of internal operation (surgical) wound, not elsewhere classified, subsequent encounter |
| T81.32XS | Disruption of internal operation (surgical) wound, not elsewhere classified, sequela |
Stopped being billable 33
| Code | Description |
|---|---|
| C83.39 | Diffuse large B-cell lymphoma, extranodal and solid organ sites |
| C86.0 | Extranodal NK/T-cell lymphoma, nasal type |
| C86.1 | Hepatosplenic T-cell lymphoma |
| C86.2 | Enteropathy-type (intestinal) T-cell lymphoma |
| C86.3 | Subcutaneous panniculitis-like T-cell lymphoma |
| C86.4 | Blastic NK-cell lymphoma |
| C86.5 | Angioimmunoblastic T-cell lymphoma |
| C86.6 | Primary cutaneous CD30-positive T-cell proliferations |
| C88.0 | Waldenstrom macroglobulinemia |
| C88.2 | Heavy chain disease |
| C88.3 | Immunoproliferative small intestinal disease |
| C88.4 | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] |
| C88.8 | Other malignant immunoproliferative diseases |
| C88.9 | Malignant immunoproliferative disease, unspecified |
| E34.0 | Carcinoid syndrome |
| E66.8 | Other obesity |
| F50.01 | Anorexia nervosa, restricting type |
| F50.02 | Anorexia nervosa, binge eating/purging type |
| F50.2 | Bulimia nervosa |
| F50.81 | Binge eating disorder |
| G90.8 | Other disorders of autonomic nervous system |
| K60.3 | Anal fistula |
| K60.4 | Rectal fistula |
| K60.5 | Anorectal fistula |
| L29.8 | Other pruritus |
| L66.1 | Lichen planopilaris |
| L66.8 | Other cicatricial alopecia |
| M51.36 | Other intervertebral disc degeneration, lumbar region |
| M51.37 | Other intervertebral disc degeneration, lumbosacral region |
| M65.9 | Synovitis and tenosynovitis, unspecified |
| Q23.8 | Other congenital malformations of aortic and mitral valves |
| Z59.7 | Insufficient social insurance and welfare support |
| Z86.010 | Personal history of colon polyps |